Why Your PD-L1 Test Results May Be Missing Critical Information – And What You Can Do About It
In the rapidly evolving world of precision oncology, diagnostic companies continue to develop sophisticated technologies to improve cancer testing. However, a critical factor impacting test accuracy is being overlooked: how your tissue is preserved before testing even begins.
The PD-L1 Detection Gap: What You Need to Know
PD-L1 testing has become essential for determining which cancer patients may benefit from immunotherapy. Yet depending on how your tumor tissue is handled, your test results could be dramatically different.
Guardant Health’s TissueNext technology uses AI-powered analysis to improve PD-L1 detection by more than 20% in non-small cell lung cancer compared to manual pathologist interpretation.
This advancement has been widely promoted as a significant breakthrough in cancer diagnostics.
But what if the issue isn’t just about better image analysis, but about the fundamental way tissues are preserved?
Groundbreaking research by Dr. Hazem Ghebeh and colleagues has revealed that when using frozen tissue specimens instead of the standard FFPE (formalin-fixed, paraffin-embedded) preservation method, PD-L1 detection rates jumped from 7-10% to 20-30% of cases using the same antibodies.
Let’s put this in perspective:
- FFPE with Standard Analysis: 7-10% of patients identified as PD-L1 positive
- FFPE with AI-Enhanced Analysis: ~12% of patients identified as PD-L1 positive (20% improvement)
- Cryopreserved Tissue: 20-30% of patients identified as PD-L1 positive (200-300% improvement)
What This Means For Cancer Patients
The implications are profound. For every 100 cancer patients tested:
- Standard FFPE testing might identify only 7-10 patients eligible for potentially life-saving immunotherapy
- AI-enhanced FFPE might identify 12 patients
- Proper cryopreservation could identify 20-30 patients
This means that even with the latest AI technology, using FFPE tissues could cause up to 18 out of 100 patients to miss out on treatments that might have helped them.
Preserving Your Options: Why SpeciCare Is Different
While diagnostic companies focus on enhancing outdated methods, SpeciCare is addressing the root of the problem. We specialize in true cryopreservation of tumor tissue, maintaining it in a viable state with molecular structures intact.
SpeciCare is currently perfecting PD-L1 testing on cryopreserved tissue, alongside developing additional advanced tests designed specifically for properly preserved specimens. We believe that combining the molecular integrity of cryopreservation with the analytical power of AI represents the future of precision oncology.
Your Cancer Journey Shouldn’t Wait For Technology To Catch Up
The most critical decision you can make happens at the time of your surgery – before any testing begins. Once your tissue is processed using FFPE methods, the opportunity for optimal preservation is lost forever.
By choosing to cryopreserve your tumor tissue with SpeciCare, you’re not just getting today’s standard of care – you’re preserving your options for tomorrow’s breakthroughs.
Take Action Now: Secure Your Cancer Care Future
- Talk to your doctor before surgery about cryopreserving your tumor tissue with SpeciCare
- Preserve your molecular options while advanced testing methods continue to evolve
- Ensure you have access to the most accurate biomarker testing as it becomes available
Even as we work to develop comprehensive testing on cryopreserved tissue, the most important step is preserving your tissue properly from the start. SpeciCare gives you control over this critical aspect of your cancer care.
The Future of Precision Oncology is Here
A new era of precision medicine is dawning – one where AI analytics and properly preserved tissue work together to reveal the full molecular profile of your unique cancer. Don’t let outdated preservation methods limit your treatment options.
Contact SpeciCare today at https://SpeciCare.com or call us at (833) 242-2873 to learn how we can help you preserve your tumor tissue and secure your place at the forefront of cancer care innovation.
Recent Comments